Amylyx Pharmaceuticals, Inc. AMLX

29.49 (0.65) (2.16%) as of 25 Sep
Market cap
$3.8B
P/E
0.0×
Insider Buys alert about insiders buying in the last 12 month
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '17
P/E ratio
— 0.00 20.51 0.00 0.00 0.00 —
P/S ratio
— 2.95 2.64 0.00 0.00 0.00 —
P/FCF ratio
— 0.00 94.26 0.00 0.00 0.00 —
P/Operating CF
— (4.37) 74.27 (42.35) (4.21) (4.21) —
P/B ratio
— 1.56 2.32 6.18 0.00 0.00 —
EV/Sales
— 0.94 1.67 0.00 0.00 0.00 —
EV/EBITDA
— 0.00 21.25 0.00 0.00 0.00 —
EV/FCF
— (0.40) 59.61 (9.64) (0.32) (0.32) —
Current Ratio
14.27 6.67 5.66 8.20 6.03 1.86 —
Net Debt/EBITDA
2.00 0.55 (12.40) 1.71 1.16 0.29 —
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.27 —
ROE
(61.59%) (100.88%) 12.73% (209.43%) 80.71% 0.00% —
ROA
(55.00%) (84.87%) 10.84% (79.82%) (146.90%) (599.55%) —
ROIC
0.00% 0.00% 39.07% 0.00% 0.00% 0.00% —
Return on Tangible Assets
(48.04%) (186.28%) 12.79% (58.67%) (99.89%) (654.08%) —
Average Days of Receivables
0.00 1.87 38.39 251.31 0.00 0.00 —
Earnings Yield
— (117.46%) 4.88% (9.53%) (73.88%) (73.88%) —
Free Cash Flow Yield
— (79.20%) 1.06% (8.67%) (63.15%) (63.15%) —
Free Cash Flow per Share
(1.31) (2.99) 0.16 (3.12) (11.41) (6.06) —
Book value per Share
3.23 2.42 6.45 5.82 13.39 0.88 —
Free Cash Flow
(123.48) (204.01) 10.68 (182.40) (75.15) (36.85) —
EV/EBIT
— 0.00 16.41 0.00 0.00 0.00 —
Other line items

Show all line items

Columns are period end dates